Pfizer’s stock hit a new 52-week low but recovered to close higher following global uncertainty caused by the tariff war and fears of a global recession. Despite a decline in COVID revenues, Pfizer’s non-COVID operational revenues improved in 2024, driven by key products in oncology. The company faces challenges such as declining COVID product sales and upcoming patent expirations, but remains attractive from a valuation standpoint and is making a comeback with a strong performance in 2024.
Full Article
Radical activist who fueled Cori Bush’s campaigns emerges as close ally of track star’s murder suspect
FIRST ON FOX: Minister Dominique Alexander, a Dallas activist known for advocating to defund the police, is publicly supporting 17-year-old Karmelo Anthony, accused of fatally stabbing Texas track star Austin Metcalf. Alexander's organization, Next Generation Action Network (NGAN), is working to facilitate Anthony's bond process, which was reduced from $1 million to $250,000. His history of activism includes close ties with former Rep. Cori Bush, and recent comments criticizing Metcalf's father have drawn attention to...
Read more